Single 25-mg Psilocybin Dose Cut Suicidal Thoughts in 75% of 20 Depressed Adults

3 articles · Updated · PsyPost · Jun 14

Twenty adults with treatment-resistant major depression and chronic suicidal ideation showed large reductions in suicidal thoughts after one 25-mg psilocybin dose plus therapy, with gains appearing within 1 week and remaining significant at 12 weeks.
By week 3, 75% met the study’s anti-suicidal response threshold and 45% reached full remission; depression scores also fell, though the early drop in suicidal thinking was slightly larger.
Safety was generally favorable: no severe adverse events or dropouts occurred, mild nausea, headache and anxiety were most common, and one participant needed anti-anxiety medication during a panic attack.
The open-label trial used no placebo and only 20 participants at one academic center, while more than half restarted psychiatric medications after week 3, limiting how firmly the 12-week benefit can be tied to psilocybin alone.
Researchers said the study addresses a population usually excluded from psychedelic trials and called for larger randomized controlled studies to test durability, safety and whether added dosing or integration support improves outcomes.

Sources

PsyPost10h ago

Psilocybin Dose Rapidly Reduces Chronic Suicidal Thoughts in Adults with Severe Depression

columbiapsychiatry.org10h ago

Psilocybin Found to Rapidly Improve Depression in Clinical Trial | Columbia University Department of Psychiatry

X10h ago

A recent study in The Journal of Clinical Psychiatry suggests that a single dose of psilocybin, paired with psychological support, may rapidly and safely reduce chronic suicidal thoughts in adults with severe,

5 Sources

Psilocybin shows promise for suicidal thoughts, yet larger trials report mixed results. What does this conflicting evidence mean for patients?

With new government support but mixed clinical data, what is the real path for psilocybin to become a standard treatment?

Psilocybin-Assisted Therapy Achieves 75% Reduction in Suicidal Ideation: Clinical Evidence, Safety, and the Road Ahead

Overview

A groundbreaking open-label trial at Sheppard Pratt’s Center of Excellence, published in June 2026, marks a major step forward in treating chronic suicidal ideation. The study specifically evaluated psilocybin-assisted therapy for people with persistent suicidal thoughts. After a single 25-mg dose of COMP360 psilocybin, participants saw rapid and substantial reductions in suicidal ideation—75% by Week 3 and 70% by Week 12. Significant improvements in overall depressive symptoms were also observed. These results highlight psilocybin’s potential as a new treatment pathway for individuals who have not responded to traditional therapies.

...